AURX Company Profile and Key Details

Average 10-day trading volume of 5.49 thousand shares is slightly above the 3-month average of 4.67 thousand, indicating heightened recent market interest.

The stock is currently mid-range between its 52-week high and low $0.77 and $3.23. With a market capitalization of about $60.51 million, Nuo Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-104.09). Key stats such as the average daily volume over the past year has been around 2.86 thousand shares, volume is running light vs its 52-week average. Headquartered in Houston, TX, Nuo Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David E. Jorden, the company employs approximately 10 people and listed since October 24, 2017. Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers 233.33% upside. The low target suggests 233.33% downside. The mean target is $3.00. This offers 233.33% upside. Nuo Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 14, 2026, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in February 25, 2026.

Nuo Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.47. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Nuo Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Nuo Therapeutics, Inc. trading at a premium to the broader market with a P/E of -30.65. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $3.00, suggesting 140.0% upside.

Nuo Therapeutics, Inc. trades at a P/E ratio of -30.65, slightly below the S&P 500 average, with a price-to-sales ratio of 11.93 and a price-to-book ratio of -40.39 indicating negative book value, which may reflect financial stress. The P/FCF stands at -25.34, also below market averages.